NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK
Clinical trials for NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK explained in plain language.
Never miss a new study
Get alerted when new NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK trials appear
Sign up with your email to follow new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising drug may halt devastating attacks in rare brain disorder
Disease control Recruiting nowThis study tests whether eculizumab can quickly reduce disability during acute attacks of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that damages the brain and spinal cord. About 110 adults who test positive for the AQP4 antibody and are having an a…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK
Phase: PHASE2 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New combo therapy aims to tame devastating nerve attacks
Disease control Recruiting nowThis study tests whether adding eculizumab to standard steroid therapy helps people with neuromyelitis optica spectrum disorder (NMOSD) recover better from sudden attacks. It involves 200 adults with a specific antibody (AQP4-positive) who are in the early phase of an attack. The…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK
Phase: PHASE4 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated May 11, 2026 20:54 UTC